NEW
YORK, July 12, 2023 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Biomea
Fusion, Inc.:
On June 23, 2023, Biomea Fusion
presented data for its Type 2 diabetes drug candidate BMF-219 at a
meeting of the American Diabetes Association. In response to the
presentation, market analysts downgraded Biomea Fusion and its
stock price fell $6.25 per share,
from $30.67 per share on June 23, 2023 to close at $24.42 per share on June
26, 2023.
Due to the forgoing, The Gross Law Firm is investigating
potential securities fraud claims on behalf of certain
Biomea Fusion investors. If you incurred a loss on your BMEA
investment, please contact us using the link below to discuss your
rights.
https://securitiesclasslaw.com/securities/biomea-fusion-loss-submission-form/?id=41986&from=4
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-biomea-fusion-inc-of-an-investigation-and-potential-class-action-lawsuit--nasdaq-bmea-301874743.html
SOURCE The Gross Law Firm